Anti-A20 Id mAb + CpG combination therapy cures large established A20 tumors using a CD8-dependent, CD4-independent mechanism. (A-B) CD8−/− mice were inoculated with 106 A20 tumor cells. When tumors reached 1 cm2 (day 0), mice were treated once intraperitoneally with anti-A20 Id mAb. CpG was given intratumorally on days 2, 3, 4, 6, and 8. Numbers in parentheses indicate animals cured by therapy. Each line in panel B represents a group consisting of 10 mice. (C-D) Balb/c mice were inoculated with 106 A20 tumor cells. Anti-CD4 mAb was administered on days −3, −2, −1, 7, 14, 28, and 35. When tumors reached 1 cm2 (day 0), mice were treated once intraperitoneally with anti-A20 Id mAb. CpG was given intratumorally on days 2, 3, 4, 6, and 8. Numbers in parentheses indicate animals cured by therapy. Each line in panel D represents a group consisting of 10 mice. (E) Splenocytes were isolated from naive mice or from tumor-bearing mice that were cured with anti-A20 Id mAb + CpG and had survived for 100 days. Splenocytes were used as effecter cells against 51Cr-labeled A20 target cells at the indicated ratio for 4 hours, and specific release of 51Cr was measured. Each line is representative of 4 mice.
